and data-driven approaches proved to be an effective technique for advancing understanding of SCFA behaviour in colon epithelial cells and to identify candidate molecular targets associated with SCFAs to act in novel chemotherapies of CRC. 1.1.2. Principle outcomes and contributions to future science and medicine This project has confirmed that different SCFAs have distinct and shared metabolic actions in colon cancer epithelial cells. The project has identified and verified a metabolic pathway by which MT structural dynamics are distinctly targeted by propionate and valerate, the chain SCFAs, in HCT116 colon cancer cells. The project has reinforced the value of employing a Systems Biology approach including computational mechanistic modelling for studying biological systems in a post-omic era. A simple but effective computational dynamical model has been developed that may be adapted for similar MT-targeted investigations. Although the evidence in this project was derived from colon cancer lines in vitro, the implications of the results may have pharmacological value for other colonic diseases, such as inflammatory bowel disease (IBD), Crohn's disease and ulcerative colitis (UC).
and data-driven approaches proved to be an effective technique for advancing understanding of SCFA behaviour in colon epithelial cells and to identify candidate molecular targets associated with SCFAs to act in novel chemotherapies of CRC. 1.1.2. Principle outcomes and contributions to future science and medicine This project has confirmed that different SCFAs have distinct and shared metabolic actions in colon cancer epithelial cells. The project has identified and verified a metabolic pathway by which MT structural dynamics are distinctly targeted by propionate and valerate, the SCFAs, in HCT116 colon cancer cells. The project has reinforced the value of employing a Systems Biology approach including computational mechanistic modelling for studying biological systems in a post-omic era. A simple but effective computational dynamical model has been developed that may be adapted for similar MT-targeted investigations. Although the evidence in this project was derived from colon cancer lines in vitro, the implications of the results may have pharmacological value for other colonic diseases, such as inflammatory bowel disease (IBD), Crohn's disease and ulcerative colitis (UC). chain